GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (OSTO:LPGO) » Definitions » Debt-to-Asset

Lipigon Pharmaceuticals AB (OSTO:LPGO) Debt-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lipigon Pharmaceuticals AB Debt-to-Asset?

Lipigon Pharmaceuticals AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Lipigon Pharmaceuticals AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Lipigon Pharmaceuticals AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was kr33.60 Mil. Lipigon Pharmaceuticals AB's debt to asset for the quarter that ended in Dec. 2023 was 0.00.


Lipigon Pharmaceuticals AB Debt-to-Asset Historical Data

The historical data trend for Lipigon Pharmaceuticals AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipigon Pharmaceuticals AB Debt-to-Asset Chart

Lipigon Pharmaceuticals AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial - - - - -

Lipigon Pharmaceuticals AB Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lipigon Pharmaceuticals AB's Debt-to-Asset

For the Biotechnology subindustry, Lipigon Pharmaceuticals AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipigon Pharmaceuticals AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipigon Pharmaceuticals AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Lipigon Pharmaceuticals AB's Debt-to-Asset falls into.



Lipigon Pharmaceuticals AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Lipigon Pharmaceuticals AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Lipigon Pharmaceuticals AB's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipigon Pharmaceuticals AB  (OSTO:LPGO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Lipigon Pharmaceuticals AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Lipigon Pharmaceuticals AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipigon Pharmaceuticals AB (OSTO:LPGO) Business Description

Traded in Other Exchanges
Address
Tvistevagen 48 C, Umea, SWE, 90736
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.

Lipigon Pharmaceuticals AB (OSTO:LPGO) Headlines

No Headlines